X Facebook LinkedIn WhatsApp Press Releases (-) Any 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 Reset 2015 October 29, 2015 argenx to Present at Key Investor Conferences October 21, 2015 arGEN-X Completes First Dosing of ARGX-113 for Severe Autoimmune Disorders February 22, 2015 arGEN-X’ Partner RuiYi, Inc. Announces First Human Dosing of Gerilimzumab, A Novel SIMPLE Antibody™ Against IL-6 August 24, 2015 arGEN-X Announces Half-Year Results For 2015 August 18, 2015 arGEN-X to Host Conference Call & Webcast to Report Half-Year Results on 26 August 2015 August 6, 2015 arGEN-X to Present at Wedbush PacGrow Healthcare Conference July 29, 2015 arGEN-X and University of Bern enter into license agreement to develop ARGX-110-based combination therapies for treatment-resistant cancers July 14, 2015 Change to the Board of Directors June 17, 2015 Preliminary Phase I results of ARGX-110 in patients with T-cell lymphomas presented at ICML May 31, 2015 arGEN-X to Present at Jefferies 2015 Global Healthcare Conference on Tuesday, 2 June at 8:00am EDT May 28, 2015 arGEN-X Presents Preliminary Efficacy and Expanded Safety Data from Phase I Trial of ARGX-111 at ASCO May 20, 2015 arGEN-X and LEO Pharma Enter into Alliance to Develop Antibody-based Treatments for Skin Conditions Pagination First page « First Previous page ‹ Previous … Page 22 Page 23 Page 24 Page 25 Current page 26 Page 27 Page 28 Page 29 Page 30 … Next page Next › Last page Last »